About Careers MedBlog Contact us

NICE Rejects Novartis's Gilenya

by Dr. Trupti Shirole on December 2, 2011 at 3:13 PM
Font : A-A+

 NICE Rejects Novartis's Gilenya

National Institute for Health and Clinical Excellence (NICE), UK has failed to back the Novartis's multiple sclerosis pill Gilenya (Fingolimod) on the grounds that it is not a cost-effective treatment option. This means patients may only be able to take Gilenya if they have private medical insurance.

Despite having offered discount, NICE estimated that the annual cost of the drug would stand around 19,196 pounds. While Novartis's competitor Biogen Idec's injectable Avonex costs 9,061 pounds


NICE's final decision is due in April. Till then Novartis has some time to either submit new data or revise its access scheme.

Source: Medindia
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

NICE Rejects Novartis's Gilenya Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests